Menatetrenone

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Menatetrenone is a form of vitamin K2 which is used in the treatment of osteoporosis to stimulate osteogenesis.

Generic Name
Menatetrenone
DrugBank Accession Number
DB12148
Background

Menatetrenone has been used in trials studying the treatment of Diabetes, Osteoporosis, Prediabetic State, and Hepatocellular Carcinoma.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 444.659
Monoisotopic: 444.302830528
Chemical Formula
C31H40O2
Synonyms
  • menatetrenona
  • Menatetrenone

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Adjunct therapy in management ofOsteoporosis•••••••••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
OrlistatOrlistat can cause a decrease in the absorption of Menatetrenone resulting in a reduced serum concentration and potentially a decrease in efficacy.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now

Categories

ATC Codes
M05BX08 — Menatetrenone
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as menaquinones. These are vitamin K2 compounds consisting of a naphtho-1,4-quinone ring system, which is substituted at the 2-position by an isoprenyl side-chain, and usually, at the 3-position by a methyl group.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Prenol lipids
Sub Class
Quinone and hydroquinone lipids
Direct Parent
Menaquinones
Alternative Parents
Diterpenoids / Naphthoquinones / Quinones / Aryl ketones / Organic oxides / Hydrocarbon derivatives
Substituents
Aromatic homopolycyclic compound / Aryl ketone / Benzenoid / Diterpenoid / Hydrocarbon derivative / Ketone / Menaquinone / Naphthalene / Naphthoquinone / Organic oxide
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
menaquinone (CHEBI:78277)
Affected organisms
Not Available

Chemical Identifiers

UNII
27Y876D139
CAS number
863-61-6
InChI Key
DKHGMERMDICWDU-GHDNBGIDSA-N
InChI
InChI=1S/C31H40O2/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-17-25(5)20-21-27-26(6)30(32)28-18-7-8-19-29(28)31(27)33/h7-8,12,14,16,18-20H,9-11,13,15,17,21H2,1-6H3/b23-14+,24-16+,25-20+
IUPAC Name
2-methyl-3-[(2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl]-1,4-dihydronaphthalene-1,4-dione
SMILES
[H]\C(CC\C(C)=C(/[H])CC\C(C)=C(/[H])CC1=C(C)C(=O)C2=CC=CC=C2C1=O)=C(\C)CCC=C(C)C

References

General References
  1. FDA Thailand Product Information: Glakay (menatetrenone) oral capsules [Link]
Human Metabolome Database
HMDB0030017
PubChem Compound
5282367
PubChem Substance
347828444
ChemSpider
4445530
BindingDB
50423776
RxNav
29495
ChEBI
78277
ChEMBL
CHEMBL259223
ZINC
ZINC000003874199
PDBe Ligand
1L3
Wikipedia
Menatetrenone
PDB Entries
7f4v

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
4CompletedTreatmentDiabetes / Impaired Glucose Tolerance1somestatusstop reasonjust information to hide
4CompletedTreatmentOsteoporosis1somestatusstop reasonjust information to hide
2, 3TerminatedTreatmentHepatocellular Carcinoma1somestatusstop reasonjust information to hide
2, 3Unknown StatusTreatmentPostmenopausal Osteoporosis1somestatusstop reasonjust information to hide

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Capsule15 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000489 mg/mLALOGPS
logP7.24ALOGPS
logP8.48Chemaxon
logS-6ALOGPS
pKa (Strongest Basic)-7.2Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area34.14 Å2Chemaxon
Rotatable Bond Count11Chemaxon
Refractivity145.51 m3·mol-1Chemaxon
Polarizability54.92 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - EI-BGC-MSsplash10-014l-9430000000-936e4020e35c79ab80a8
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-000b-1239300000-7dce9707a659e252c294
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-0200900000-4106f8b213d509dcf3bc
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0api-2209100000-45a76b66386f8f49bfb4
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-000i-0924500000-9eec7db941fa087620f1
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-052s-2944100000-1d2441b1c81a84692a35
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0m2a-2729300000-2186912b020d66040162
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-220.2000275
predicted
DarkChem Lite v0.1.0
[M-H]-235.4212275
predicted
DarkChem Lite v0.1.0
[M-H]-219.28148
predicted
DeepCCS 1.0 (2019)
[M+H]+220.6737275
predicted
DarkChem Lite v0.1.0
[M+H]+234.1623275
predicted
DarkChem Lite v0.1.0
[M+H]+221.2728
predicted
DeepCCS 1.0 (2019)
[M+Na]+220.7149275
predicted
DarkChem Lite v0.1.0
[M+Na]+235.5432275
predicted
DarkChem Lite v0.1.0
[M+Na]+227.01323
predicted
DeepCCS 1.0 (2019)

Drug created at October 20, 2016 21:28 / Updated at May 21, 2021 10:22